Aktie APHB AMPLIPHI BIOSCIENCES CORP
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Ampliphi Biosciences Corp OTC Bulletin Board

Aktien

APHB

US03211P1030

APHB

Schlusskurs OTC Bulletin Board
Andere Börsenplätze
- USD - Intraday Chart für Ampliphi Biosciences Corp
21.03. Armata Pharmaceuticals, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
21.03. Armata Pharmaceuticals, Inc. meldet Ergebnis für das vierte Quartal zum 31. Dezember 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000
Armata Pharmaceuticals : Shareholder Meeting - Form 8-K
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus
Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
Armata Pharmaceuticals, Inc. Announces CFO Changes
Armata Pharmaceuticals, Inc. Announces Executive Changes
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
Armata Pharmaceuticals, Inc. Announces That It Has Entered into A Credit and Security Agreement with Innoviva Strategic Opportunities Llc
Armata Pharmaceuticals, Inc. Announces Executive Changes
Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PKLC Aktie
  4. APHB Aktie
  5. Nachrichten Ampliphi Biosciences Corp
  6. Andere Sprachen